Aptevo Therapeutics (APVO) Other Accumulated Expenses (2016 - 2026)

Aptevo Therapeutics has reported Other Accumulated Expenses for 11 years, with the latest figure at $413000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses fell 63.52% year-over-year to $413000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $413000.0 (down 63.52% YoY) and the FY2025 annual result came in at $252000.0, down 30.58% from the prior year.
• Other Accumulated Expenses improved to $413000.0 in Q1 2026 per APVO's latest filing, from $252000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $1.6 million in Q1 2022 and troughed at $30000.0 in Q2 2022.
• A 5-year average of $936235.3 and a median of $1.0 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses slumped 96.96% in 2022, then soared 2386.67% in 2023.
• Over 5 years, Other Accumulated Expenses stood at $1.1 million in 2022, then increased by 3.63% to $1.1 million in 2023, then sank by 68.21% to $363000.0 in 2024, then tumbled by 30.58% to $252000.0 in 2025, then jumped by 63.89% to $413000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $413000.0, $252000.0, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.